Please login to the form below

Not currently logged in
Email:
Password:

Yervoy

This page shows the latest Yervoy news and features for those working in and with pharma, biotech and healthcare.

GSK discontinues two feladilimab trials in head and neck cancer

GSK discontinues two feladilimab trials in head and neck cancer

An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had previously been

Latest news

More from news
Approximately 37 fully matching, plus 151 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better long-term survival than the Keytruda/chemotherapy combination which is driving the growth

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    In June 2018, Bristol Myers-Squibb sought approval for Opdivo and low-dose Yervoy in lung cancer in patients with a TMB of greater than ten mutations per megabase. ... impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    drug Yervoy (ipilimumab) in an early-stage trial.

  • Pharma deals in February 2015 Pharma deals in February 2015

    As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.

  • Pharma deals during July 2014 Pharma deals during July 2014

    Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is FDA approved for late-stage melanoma.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics